Question-and-Answer Session
Operator
And your first question comes from the line of Lisa Gill of JPMorgan. Please proceed.
Lisa Gill - JPMorgan
Thanks very much and good morning. Thanks, George, for all the detail around the distribution component of the business, but I'm just wondering, can you maybe just talk to us a little bit about direct store sales. You said they were up 10 basis points. What was the primary driver there, would be my first question?
And then secondly, as we think about Pfizer moving to a fee-for-service agreement and we look at Pfizer and Wyeth coming together, can you talk about any potential impact that you believe that those two entities coming together will have on what fee-for-service agreements will look like? So for example, what does Wyeth look like today and what do you think that the new agreement will look like?
And then just one last follow-up for Dave, you talked about the fact that Pyxis not seeing as much impact from a purchasing perspective and some of the other capital areas. Is that because of the price point or is there something else that is still driving hospitals to buy the Pyxis technology? Thanks.
George Barrett
Good morning, Lisa. Let me try to deal with the first two pretty quickly. Yeah, the growth in our operating margin related to our DSD business is largely about mix. It's a combination of the flow of generic products as well as the growth of larger independent accounts. As I mentioned, we're getting a little bit of shift in our business and some of that the independents that we're picking up are actually more robust than the ones that we've been losing. So it's a bit of mix shift is primarily what's going on and a real focus on dropping that business.
As relates to your second question, I can't give you, as it relates to a fee-for-service agreement with any specific company, I won't name companies. I don't think it's appropriate. What I can say as we look at the Pfizer or Wyeth transaction. Obviously these are both large and good partners of ours.
And it's premature to describe at this point what any impact might look like from the connection of those businesses -- but the combination of those businesses, but at this point, I would not expect this to be an extraordinary event for us.
Lisa Gill - JPMorgan
- To read the full transcript on Seeking Alpha, click here »
